Newsletter March 2010

Read about novel platforms, models, technologies, and services offered by Bioneer.

New possibilities in targeting the human immune system

Bioneers human dendritic cell models now include a Th2 and a Th17 response model. Bioneers predictive human DC models are suitable for screening of drug candidates, probiotic strains or other active ingredients.
DCs are the most potent antigen presenting cells of the immune system and they are responsible for activation of the adaptive immune system in response to infections. DCs are among the key regulators of the immune system in immunological disorders such as autoimmune and allergic diseases and are thus promising targets for treatment of these disorders. Bioneer now offers immune models of Th1, Th2 and Th17 phenotypes.

Click here for more information on the Th2 and Th17 response models

Experienced formulation specialist joins Bioneer:FARMA

Bioneer now offers expert drug formulation assistance of the experienced international formulation specialist Dr. Daniel Bar-Shalom. His research and development activities are focused on oral drug delivery, drug administration, and chemotherapy. Daniel Bar-Shalom has previously been with IPC International Operations and Egalet, of which he is also the founder. He holds a degree in pharmacy and biology and has published a range of scientific papers and patents.
Daniel Bar-Shalom joined Bioneer as Research Scientist on 1st of January 2010.

Click here for more information on Bioneer:FARMA services in drug formulation

Novel promising protein drug targets for inflammation

Bioneer has generated novel proteomic data, based on analysis of changes in the expression levels of a large number of different proteins within activated dendritic cells. Changes in the expression levels of specific proteins have the potential to reveal novel drug targets or biomarker molecules. The potential drug targets were discovered by Bioneer and The University of Southern Denmark in the framework of "Centre for Immunomics", an industrial innovation consortium funded by the Danish Agency of Science, Technology and Innovation.  The consortium consists of Ferrosan, Action Pharma, MediMush, Danisco, University of Copenhagen, and University of Southern Denmark (SDU) and is headed by Bioneer. Bioneer facilitates the commercialization of these drug targets. Please contact Bioneer for further information on these novel  drug targets.

Danish Stem Cell Initiative kick off

A grant of sixty five65 million DKK will soon be allocated for the establishment of one Danish national centre for stem cell research. The Strategic Research Council is responsible for formulating the call which is expected to be launced in February/March 2010. The initiative will be strongly focused towards translational research, i.e. clinical applications of stem cells and will involve participation of clinical research units at hospitals, university research units and private companies. The basis for the grant was established by the work of Bioneer, several Danish Univerties and hospitals, and companies through the "Danish National Stem Cell Initiative - Start" which contain an analysis of possibilities for Denmark within the stem cell area and a prososal for actions to be undertaken by Denmark to establish a powerful platforms within regenerative therapy.

Read more

FDA sponsors Bioneer:FARMA development on Quality-by-Design

The American Food and Drug Administration (FDA) has donated $ 169.000 to the Pharmaceutical Faculty at the University of Copenhagen. The FDA-grant will facilitate the development of new tools for predicting oral bioavailability of drug candidates and improve the Quality-By-Design concept.
FDA has initiated a new strategy - Quality by Design - seeking novel and better in vitro prediction methods for drug absorption. These research activities will be performed in a close collaboration between regulatory authorities (FDA), The Pharmaceutical Faculty of Copenhagen University and Bioneer:FARMA. The project is headed by Dr. Anette Müllertz from Bioneer:FARMA. The new models derived in this project will be available to clients by the second half of 2010.

Click here for more information concerning Quality-by-Design (FARMA's homepage, in Danish)

Meet us at:

BIO-Europe, Spring 2010 in Barcelona
WIRM IV -Innate and Adaptive Immunoregulatory Mechanisms 2010 in Davos